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H3.3K27M cooperates with Trp53 loss and PDGFRA gain in mouse 
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gliomas  
 
Manav Pathania1, Nicolas De Jay2#, Nicola Maestro1#, Ashot S. Harutyunyan2, Justyna 
Nitarska3, Pirasteh Pahlavan4, Stephen Henderson5, Leonie G. Mikael2, Angela Richard-
Londt6, Ying Zhang6, Joana R Costa3, Steven Hébert7, Sima Khazaei2, Nisreen Samir 
Ibrahim2, Javier Herrero5, Antonella Riccio3, Steffen Albrecht8, Robin Ketteler3, Sebastian 
Brandner6, Claudia L. Kleinman2,7^, Nada Jabado2,9^*, and Paolo Salomoni1,4,10^* 
 
1Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, London, WC1E 6DD, United 
Kingdom 
2Department of Human Genetics, McGill University, Montreal, QC, H3A 1B1, Canada 
3MRC Laboratory for Molecular Cell Biology, UCL, London, WC1E 6BT United Kingdom 
4German Centre for Neurodegenerative Diseases (DZNE), Bonn, 53127, Germany  
5Bill Lyons Informatics Centre, UCL Cancer Institute, London, WC1E 6DD, United Kingdom 
6UCL Institute of Neurology, London, WC1N 3BG, United Kingdom 
7The Lady Davis Institute, Jewish General Hospital, Montreal, QC, H3T 1E2, Canada 
8Department of Pathology, McGill University, Montreal, QC, H3A 2B4, Canada 





*To whom correspondence should be addressed 
Paolo Salomoni, p.salomoni@ucl.ac.uk 







Gain-of-function mutations in histone 3 (H3) variants are found in a substantial 
proportion of pediatric high-grade gliomas (pHGG), often in association with TP53 loss and 
PDGFRA amplification. Here, we describe a somatic mouse model wherein H3.3K27M and 
Trp53 loss alone are sufficient for neoplastic transformation if introduced in utero. H3.3K27M-
driven lesions are clonal, H3K27me3-depleted, Olig2-positive, highly proliferative and 
diffusely spreading, thus recapitulating hallmark molecular and histopathological features of 
pHGG. Addition of wild-type PDGFRA decreases latency and increases tumor invasion, 
while ATRX knockdown associates with more circumscribed tumors. H3.3K27M-tumor cells 
serially engraft in recipient mice and preliminary drug screening reveals mutation-specific 
vulnerabilities. Overall, we provide a faithful H3.3K27M-pHGG model which enables insights 
into oncohistone pathogenesis and investigation of future therapies.  
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Mutations in histone 3 variants are believed to drive development of high-grade 
glioma in children. Despite extensive efforts, no truly representative model demonstrating the 
oncogenic activity of mutant histone 3 variants has been described. Here we report a 
somatic mouse model of oncohistone-driven tumorigenesis that recapitulates hallmark 
features of human pHGG. Our findings support the concept that these mutations act 
specifically in utero to drive changes in neurodevelopmental programs that lead to full blown 
transformation postnatally. Ultimately, this model provides insights into mechanisms of 
transformation in the brain and may enable identification of targets for more effective 





Pediatric High-Grade Glioma (pHGG) is a devastating disease representing the 
primary cause of cancer death in children (Ostrom et al., 2015; Ostrom et al., 2016). Despite 
striking molecular differences in their pathogenesis, current therapeutic approaches still 
follow recommendations for adult HGG and involve radiation therapy and other cytotoxic 
regimens (Faury et al., 2007; MacDonald et al., 2011; Paugh et al., 2010; Qu et al., 2010). 
Our group and others uncovered recurrent, somatic, gain-of-function mutations in H3 
variants in pHGG (Schwartzentruber et al., 2012; Sturm et al., 2012; Wu et al., 2012). Two 
mutations lead to specific amino acid changes in key residues of H3 variants and in specific 
brain regions. Indeed, more than 90% of pHGG in the brain midline, including the particularly 
deadly diffuse intrinsic pontine gliomas (DIPG), carry lysine 27 to methionine (K27M) 
mutations in an H3 variant (H3F3A/H3.3, HIST1H3B or HIST1H3C/H3.1 and rarely 
HIST2H3B/H3.2), while mutations of glycine 34 to arginine or valine (G34R/V) in H3.3 occur 
in 36% of pHGG in the cerebral hemispheres (Fontebasso et al., 2013; Fontebasso et al., 
2014; Khuong-Quang et al., 2012; Schwartzentruber et al., 2012; Sturm et al., 2012). These 
“oncohistones” are found almost exclusively in pHGG and are mutually exclusive with the 
recurrent mutations in isocitrate dehydrogenase enzymes (IDH) identified in young adult 
gliomas (Yan et al., 2009), and the epigenetic heterogeneity seen in adult glioma (Gallo et 
al., 2015). 
H3.3 is the predominant H3 variant mutated in pHGG and is a replication-
independent histone variant loaded onto chromatin throughout the cell cycle predominantly 
by two distinct chaperone complexes, formed by either histone cell cycle regulator 
(HIRA)/Calcineurin binding protein 1 (CABIN1)/Ubinuclein (UBN1) or the death domain 
associated protein (DAXX)/-thalassemia/mental retardation syndrome X-linked (ATRX) 
(Michod et al., 2012; Yuen and Knoepfler, 2013). H3.3 dynamically regulates gene 
transcription through both its post-translational modifications (PTMs) as well as its turnover 
within nucleosomes in a variety of cell types (Maze et al., 2014; Maze et al., 2015). While the 
function of H3.3G34R/V is still unclear, H3.3K27M has been shown to have gain-of-function 
activity inhibiting the Polycomb Repressive Complex 2 (PRC2) (Bender et al., 2013; Lewis et 
al., 2013), which in turn leads to a global reduction in H3K27me3 levels in primary tumors 
and tumor-derived primary cells. Rescue of H3K27me3 levels via pharmacological inhibition 
of H3K27me3 demethylases has anti-tumor effects against primary H3.3K27M pHGG cells, 
suggesting addiction to this mutation within established tumors (Hashizume et al., 2014). 
H3.3K27M pHGG cells are also sensitive to inhibition of histone deacetylases and menin, 
indicating the involvement of additional epigenetic changes in sustaining tumor growth 
(Funato et al., 2014; Grasso et al., 2015).  
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H3.3K27M-tumors and IDH-mutant gliomas possess co-occurring mutations in the 
same genes (Fontebasso et al., 2014; Khuong-Quang et al., 2012; Nikbakht et al., 2016; Wu 
et al., 2014). These include alterations affecting the p53 pathway in ~87% of H3.3K27M 
tumors (Fontebasso and Jabado, 2015; Fontebasso et al., 2014; Nikbakht et al., 2016) and 
loss-of-function mutations in ATRX, which occur with increasing frequency in older patients 
(Fontebasso et al., 2014; Khuong-Quang et al., 2012; Nikbakht et al., 2016). Moreover, 
amplifications and rare mutations of the platelet-derived growth factor receptor alpha gene 
(PDGFRA) often co-occur with H3.3K27M and TP53 mutations, indicating a potential role of 
this receptor in tumorigenesis (Flavahan et al., 2016; Khuong-Quang et al., 2012; Korshunov 
et al., 2015; Paugh et al., 2013).  
H3.3 mutations are likely tied to the action of specific developmental programs. 
Attempts to model H3.3K27M-driven HGG formation in vivo via genetic recombination in neural 
progenitor/stem cells (NPCs) in the postnatal brain failed to demonstrate tumor-driving 
activity (Lewis et al., 2013), suggesting that the mutation event leading to HGG may actually 
occur during embryogenesis. A recent study reported that transduction of human embryonic 
stem cell-derived NPCs with H3.3K27M, p53 shRNA and constitutively active, mutant 
PDGFRAD842V led to neoplastic transformation, but only via in vitro passaging over several 
months (Funato et al., 2014). Furthermore, when transplanted into recipient 
immunocompromised mice, these genetically modified NPCs gave rise exclusively to low-
grade glioma (LGG), not high-grade as seen in patients. Other attempts to model H3.3K27M-
DIPG in vivo have required constitutive expression of the PDGF-B ligand, which is not 
present in pHGG and can induce tumors even with wild-type (WT) H3.3, suggesting that 
PDGFRA signalling drives rapid tumorigenesis and H3.3K27M is secondary in these models 
(Cordero et al., 2017; Hennika et al., 2017). 
The lack of a truly representative in vivo model for mutant H3.3K27M-driven HGG limits 
our ability to dissect the underlying mechanisms instructing this archetypal epigenetic cancer 
and impedes our ability to develop therapies that have the best chance of success in the 
clinic. The main goal of the present study is to generate a mouse model recapitulating the 
histological and molecular characteristics of human H3.3-mutated pHGG.  
 
Results 
H3.3K27M and Trp53 loss induce diffuse tumorigenesis in both hindbrain and forebrain  
To generate a mouse model of oncohistone pathogenesis, we employed several 
approaches. First, we knocked H3.3K27M into the H3f3a locus in mouse ES cells using Zinc 
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Finger Nuclease technology (ZFN). However, this approach caused a severe embryonic 
phenotype wherein zygotes did not grow past the 4-cell stage (Figure S1A). Targeted 
expression of H3.3K27M downstream from either the Nes or Gfap promoter, which are active 
in both NPCs during development and the postnatal brain, also failed to induce tumors in 
mice up to 18 months old, even when the H3.3K27M transgene was expressed in combination 
with Trp53 loss (Figure S1B and data not shown). We also attempted a focal, somatic 
approach, based on in vivo electroporation of transposable vectors using the Sleeping 
Beauty (SB) system. Intracranial delivery and electroporation of SB-transposable H3.3K27M-
encoding vectors together with ATRX/p53 knockdown constructs in neonatal mice generated 
small proliferative lesions around the injection site but failed to induce tumors (Figure S1C-
E), in accordance with previous reports based on the Replication-Competent ASLV long 
terminal repeat (LTR) with a Splice acceptor (RCAS) system (Lewis et al., 2013).  
Based on these findings, we reasoned that the cell of origin of pHGG is likely an 
embryonic precursor cell. To test this hypothesis, we performed in utero electroporation 
(IUE) of piggyBac transposon-based vectors (Chen et al., 2014; Chen and LoTurco, 2012) at 
E12.5-E13.5 to permanently overexpress GFP (empty vector), H3.3WT or H3.3K27M in NPCs 
and their progeny. As IUE carried out during neural development specifically targets 
transgenes to NPCs lining the ventricles (Saito and Nakatsuji, 2001; Tabata and Nakajima, 
2001), only NPCs integrate the mutation-carrying transposons. After electroporation, the 
non-integrating transposase is rapidly diluted and the integrated mutation-carrying 
transgenes are stably inherited by successive progenies of the electroporated NPCs. Given 
that H3.3K27M tumors are predominantly found in the brain midline and pons, we used 
piggyBac IUE to target NPCs in the lower rhombic lip of the developing hindbrain, which 
contributes to the pontine nuclei as development proceeds (Figure 1A). We tested whether 
two drivers, transposable H3.3K27M and Trp53 loss using a non-transposable gRNA/Cas9 
targeting the Trp53 locus (K27M-P, 2-hit), were sufficient to induce tumorigenesis in either 
hindbrain or cortex. Hindbrain IUE was performed at E12.5 and forebrain IUE was performed 
at E13.5, in order to introduce mutant H3.3K27M at the peak of cortical or pontine 
neurogenesis, respectively (Finlay and Darlington, 1995; Shinohara et al., 2013). Neoplastic 
transformation occurred with 100% penetrance in both hindbrain (Figure 1B and 1C) and 
cortex (Figure 1D), 6 and 8 months following surgery, respectively (Table S1). No tumors 
formed with empty vector GFP (EV), H3.3WT or H3.3G34R in combination with Trp53 loss 
(Table S1). Specifically, GFP+ K27M-P cells proliferated ectopically in both anatomical 
compartments, inducing both focal and diffuse tumors in the hindbrain and mainly diffuse 
tumors in the cortex (Ki67+; Figure 1B-D; Table S1). The hindbrain tumors also spread into 
the cerebellum and fourth ventricle (Figure 1C). Analysis of expressed variants by RNA-Seq 
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showed no evidence of spontaneous mutations or CRISPR/Cas9 off-target effects that could 
underlie transformation (Table S2). Spontaneous non-recurrent events were detected in 11 
genes that did not include oncogenes or tumor suppressors (Table S2). These data 
demonstrate that two genetic hits alone, H3.3K27M and Trp53 loss, can induce tumorigenesis 
in both supra- and infratentorial locations, suggesting that NPCs can be transformed by 
these genetic changes independent of anatomic location. 
 
Tumorigenesis induced by H3.3K27M in combination with Trp53 loss and ATRX 
knockdown  
As H3.3-mutated pHGG is often associated with loss-of-function mutations in the 
chromatin-associated factor and H3.3 co-chaperone ATRX, we decided to model this 
additional genetic change using IUE. Based on similar transformation potential in both 
hindbrain and cortex and the important technical challenges of brainstem electroporations, 
we subsequently focused on forebrain electroporations at E13.5. We concomitantly 
introduced non-transposable gRNA/Cas9 targeting the Trp53 locus and a transposable 
shRNA against ATRX together with H3.3K27M (EV-AP/WT-AP/K27M-AP; 3-hit; Figure 2A). In 
GFP+ cells sorted and expanded from embryonic cortices 72 hr following IUE, efficient 
expression of HA-tagged H3.3WT, H3.3G34R or H3.3K27M and concomitant knockdown of both 
p53 and ATRX protein levels could be observed (Figure 2B).  
 Following IUE, mice were allowed to deliver normally and were assessed at postnatal 
day 21 (P21), 4 months and 8-10 months of age. In H3.3K27M ATRX/p53-KD mice (K27M-
AP), Ki67+ cells were marginally increased by P21. By 4 months, K27M-AP mice developed 
neoplastic lesions in the cortex and striatum (Figure 2C, orange arrowheads; Figure 2D) with 
100% penetrance. These proliferative lesions were either focal (Figure 2C; left K27M-AP 
panel) or diffuse (Figure 2C; right K27M-AP panel). In both cases, small clusters of 
GFP+Ki67+ cells were also seen migrating along the corpus callosum into the contralateral 
cortex (Figure 2C, red arrows), mirroring the invasive nature of human pHGG. 20% of GFP+ 
cells were Ki67+ and Nestin+ in ectopic, non-neurogenic locations, thereby demonstrating 
stem cell-like characteristics (Figure 2D and 2E) and neoplastic transformation. In contrast, 
we did not observe GFP+Ki67+ cells outside the proliferative regions of the subventricular 
zone (SVZ) and dentate gyrus (DG) in EV-AP, WT-AP or G34R-AP (Figure S2A and S2B; 
Table S1). We also noted that WT-AP mice displayed a premature differentiation effect, with 
fewer GFP+ cells in the cortex and a larger neuron-to-astrocyte ratio at 4 months compared 
to EV-AP (Figure 2C and Figure S2A-C). In the olfactory bulb (OB) at 4 months, number of 
GFP+ neurons was decreased in WT-AP or K27M-AP compared to EV-AP (Figure S2D), 
 7 
correlating with altered neurogenic properties of NPCs in the SVZ upon H3.3 overexpression 
or mutation. By 9 months, the smaller proliferative lesions in K27M-AP cortex and striatum 
had progressed to fully developed HGG, with mice displaying neurological signs requiring 
euthanasia. These lesions were positive for Ki67, Olig2, Nestin and HA; and were depleted 
of K27me3 signal (Figure 2F). Tumors in these animals were also ATRX-depleted, as 
expected, and showed increased proliferation and contralateral infiltration, thus resembling 
H3.3K27M pHGG, (Figure 2G). Taken together, these data indicate that in utero delivery of 
H3.3K27M, ATRX knockdown and Trp53 loss can induce glioma by 4 months. 
  
PDGFRAWT overexpression shortens latency of tumorigenesis 
PDGFRA plays a major role in early brain development and whilst activating 
mutations are rare, amplifications of the PDGFRA locus are often seen in pediatric glioma in 
the context of H3.3 mutations (Fontebasso et al., 2014; Khuong-Quang et al., 2012; Paugh 
et al., 2013; Wu et al., 2014). To determine whether overexpression of PDGFRA further 
modifies the tumorigenic properties of the K27M-AP (3 hit) model, we overexpressed a WT 
PDGFRA cDNA using piggyBac IUE (EV/WT/K27M-APP; 4-hit; Figure 3A and 3B). 
Overexpression of PDGFRA at E13.5 in all conditions greatly increased the numbers of 
neurons, astrocytes and oligodendrocytes in the electroporated region at both P21 and 4 
months, when compared to the K27M-AP/3-hit model (Figure 3C vs Figure 2C). It also 
increased the thickness of the electroporated neocortex as well as the size of the ipsilateral 
hemisphere in relation to the contralateral hemisphere (Figure 3C). In several cases, this 
effect was so extensive that the lateral ventricle became occluded with supernumerary 
striatal cells on the electroporated side (Figure 3C). At P21, ectopic proliferation was only 
seen in K27M-APP-electroporated animals (Figure 3C), showing a significantly decreased 
latency compared to the K27M-AP model where ectopic proliferation was only seen at 4 
months (Figure 3C vs Figure 2C). By 4 months, 100% of K27M-APP animals developed 
extensive proliferative lesions migrating into the contralateral hemisphere (Figure 3C; Table 
S1). 15% of cells in these lesions were Ki67+GFP+ (Figure 3D and 3E), and as expected, 
had increased levels of PDGFRA (Figure 3D). At 4 months, EV-APP and WT-APP brains 
also showed low-penetrance tumors (10-25%; Table S1), but penetrance did not increase up 
to 8-10 months. This is in contrast to K27M-APP which showed 100% tumor penetrance at 4 
and 8-10 months (Table S1). By 9 months, K27M-APP tumors were significantly progressed, 
with very high numbers of Ki67+Nestin+ cells and multiple necrotic foci (Figure 3F and 3G). 
These lesions were intermittently positive for GFAP, but were universally depleted of MBP 
and K27me3 signal (Figure 3G). Histology revealed K27M+ and Ki67+ cells colocalizing with 
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GFP (Figure 3H). Thus, addition of WT PDGFRA shortens the latency of tumorigenesis and 
acts synergistically with H3.3K27M to transform NPCs in vivo. 
We then investigated PDGFRAD842V activating mutations previously shown to 
cooperate with H3.3K27M and p53 knockdown to induce transformation in human NPCs in 
vitro (Funato et al., 2014). In contrast to WT PDGFRA, overexpression of PDGFRAD842V led 
to 100% penetrant, high-grade lesions also in WT-APP and EV-APP mice (Figure S3A and 
S3B, Table S1), suggesting that, unlike WT PDGFRA, PDGFRAD842V does not require 
H3.3K27M to drive tumorigenesis in vivo (Cordero et al., 2017; Hennika et al., 2017; Paugh et 
al., 2013). 
 
H3.3K27M tumor cells can serially engraft in recipient mice and can be used for targeted 
drug screening 
Next, we set out to determine the engrafting capacity of H3.3K27M-driven tumor cells 
upon orthotopic transplantation as further proof of their neoplastic nature. K27M-P, K27M-AP 
and K27M-APP tumor cells were injected into the striatum of NOD-SCID mice, and brains 
were collected 45-70 days after transplantation. Histopathological analysis revealed that 
K27M-P, K27M-AP and K27M-APP cells formed 100% diffuse tumors with extensive 
spreading through striatal, dorsolateral and dorsomedial cortical regions, similar to what is 
observed in pHGG (Figure 4A and 4B) (Buczkowicz et al., 2014; Louis et al., 2016; Nikbakht 
et al., 2016).  
  To demonstrate the utility of our model for high-throughput screening approaches, we 
performed a proof-of-principle comparison of the sensitivity of K27M-AP and K27M-APP 
tumor cells to a library of 430 small molecule kinase inhibitors (Figure 4C and 4D; Figure S4; 
Table S3). This library was chosen as kinases are actionable and several have been 
implicated in pHGG. Results revealed a specific vulnerability of K27M-AP tumor cells to 
Vacquinol-1, compared to WT-AP cells (Figure 4D and 4E; Table S3; z-score 0.98). In 
addition, K27M-APP were specifically vulnerable to Akt inhibition using Akti-1/2, compared to 
WT-APP cells (Figure 4D and 4E; Table S3; z-score 0.96). These preliminary results 





H3.3K27M-mediated tumorigenesis in mice is clonal, recapitulates features of invasive 
human pHGG 
 To address the clonal evolution and/or the homogeneity of the mutational landscape 
of H3.3K27M tumors, we performed whole exome sequencing (WES) of 10 biopsies from a 
K27M-AP tumor, spatially distributed along the rostral-caudal axis (Figure S5A). Single 
nucleotide variants (SNVs) exhibited very high concordance across all samples (≥ 98% 
concordance between any pair of biopsies, Table S4). Clonality analysis revealed 7 distinct 
clusters of non-synonymous, exonic SNVs, and 6 of 7 clusters exhibit a consistent cellular 
prevalence across all biopsies (Figure S5B). The cellular prevalence of the remaining minor 
cluster varied between 25% and 40%, with no variant belonging to this cluster 
overrepresented in any of the samples (Figure S5A and S5B).  Altogether, these results 
indicate that H3.3K27M-driven tumors are clonal and derive from the originating mutations 
introduced during IUE. 
 Given that H3K27me3 levels are drastically decreased in human H3.3K27M gliomas 
due to the inhibitory effect of this mutant histone on EZH2 (Lewis et al., 2013), we analyzed 
this mark in 2-, 3- and 4-hit H3.3K27M  cells. Ex vivo, H3K27me3 levels were reduced in 
preneoplastic NPCs and further reduced in cells isolated from K27M-P, K27M-AP and 
K27M-APP tumors (Figure 5A). In vivo, H3K27me3 levels were also depleted in K27M-AP 
and K27M-APP cells compared to WT-AP and WT-APP cells at 4 months and 21 days, 
respectively (Figure 5B and 5C). Furthermore, this depletion was progressive, as in 10-
month K27M-AP tumors there was further depletion of this repressive PTM compared to 
tumors at 4 months (K27M-AP vs K27M-AP tumor 10 mo.; Figure 5C). We also observed 
that K27M-AP and K27M-APP cells preferentially migrated along CD31+ blood vessels 
(Figure 5D and 5E).  
K27M-AP and K27M-APP tumors were also significantly enriched in cells expressing 
Olig2, similar to human DIPG (Figure 6A and 6B). The increase in Olig2 expression was 
associated with extensive migration away from the electroporation site in K27M-APP cells, 
as more Olig2+GFP+ cells were seen in the contralateral cortex compared to the ipsilateral 
one (Figure 6B). In contrast, this contralateral migration or invasion never occurred in EV-
APP or WT-APP at 4 months. We confirmed the increased invasiveness of K27M-APP vs 
K27M-AP tumor cells in vitro (Figure 6C). The extent of GFP+ cell migration was also 
increased in vivo in K27M-APP brains compared to EV-APP and WT-APP (Figure S6A and 
S6B). Migration into the OB was also increased in K27M-APP (Figure S6C). Furthermore, 
ATRX knockdown conditions (K27M-AP and K27M-APP) generated increased numbers of 
focal or localized cortical tumors compared to K27M-P (0% K27M-P vs 65% K27M-AP; 
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Table S1 and Figure 6D, p<0.0001). These data demonstrate that K27M-AP and K27M-APP 
tumors progressively lose H3K27me3 genome-wide as transformation proceeds, that K27M-
APP tumor cells are intrinsically more invasive than K27M-AP cells, and that addition of 
ATRX knockdown to H3.3K27M and Trp53 loss can reduce the diffuse nature of the resulting 
lesions.  
 
Molecular cross-species analysis shows that H3.3K27M mouse tumors recapitulate 
human H3K27M pHGG and uncovers disease-associated pathways  
 To identify specific genes and pathways deregulated in preneoplastic and tumor 
models, we performed genome-wide transcriptional profiling (RNA-seq) of GFP+ cells sorted 
and expanded ex vivo from embryonic cortices of electroporated mice at 72 hr 
(preneoplastic) and 5-9 months (tumor) post-IUE. Principal component analysis (PCA) and t-
Distributed Neighbor Embedding (t-SNE) revealed that H3.3K27M induced global changes in 
gene expression, with K27M cells segregating from controls (Figure 7A and 7B). We 
observed a progression from the untransformed to the transformed state, with large 
transcriptional changes evident already at the preneoplastic stage. Cells harboring three hits 
(K27M-AP) showed a variable degree of transformation (Figure S7A), while cells harboring 
all four hits (K27M-APP) consistently clustered close to H3.3K27M-transformed tumor cells 
(Figure S7A and Figure 7A and 7B), in line with the shorter latency observed for PDGFRA 
expressing tumors. Elevated levels of PDGFRA were confirmed in RNA-seq data (Figure 
S7B). 
To directly assess the disease relevance of our mouse models, we derived gene 
signatures based on the human orthologs of differentially expressed genes in the mouse 
models (Table S5). Our results show that the global H3.3K27M-dependent transcriptional 
changes were recapitulated in human tumors (Figure 7). PCA and t-SNE of human samples 
based on the expression of human orthologs of the murine K27M tumor signature (K27M-T) 
clearly segregated normal brain, H3.3WT and H3.3K27M pHGG (Figure 7C, Figure S7C-E). We 
then focused on individual genes to identify those that were consistently deregulated in 
mouse and human samples (preserved direction of change; statistical significance with 
adjusted p<0.05). Figure 7D shows that human tumors bearing the K27M mutation had the 
largest overlap with murine K27M tumor signatures (significant overlap p<0.0001; 2.6 times 
larger than with WT pHGG; Table S6), indicating that the genes identified in our mouse 
models specifically reflect K27M human tumor biology and not merely a general oncogenic 
transformation. 
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To validate this result and identify specific pathways recapitulated in pHGG, we 
performed functional annotation of the murine K27M-T signature (Table S7), and assessed 
the concordance of specific sets of genes in pHGG through single-sample gene set 
enrichment analysis (ssGSEA) (Barbie et al., 2009) and through direct assessment of 
expression changes in H3.3K27M pHGG relative to normal brain. Among the deregulated 
genes consistent with human pHGG, we identified groups of genes related to chromatin 
developmental pathways including Wnt and Hox genes, DNA binding, extracellular matrix 
proteins and signal peptides (Figure 7E, Figure S7F, Table S7). 
In human H3.3K27M pHGG, H3K27me3 levels are significantly reduced. We used 
ChIP-seq to assess K27me3 levels in H3.3K27M-expressing tumor and preneoplastic cells, 
H3.3WT and EV cells. We observed marked overall downregulation of H3K27me3 in H3.3K27M 
samples (Figure 8A), confirming the reduction seen by immunofluorescence (Figure 5C) and 
mirroring findings in human H3.3K27M pHGG . 
This decrease affected the promoter region of a large proportion of the genes, with a 
clear depletion of the mark surrounding their transcription start sites (TSS). Clustering of 
genes based on K27me3 patterns revealed that loss of the mark at the TSS is associated 
with upregulation of expression (clusters M1-M3; Figure 8B and Figure S8A and S8B), 
consistent with the repressive role of this mark. On the other hand, genes with lower levels 
of K27me3 in WT samples (clusters M5-M7, M10-M12; Figure S8A and S8B) or situated at 
K27me3 boundaries (cluster M4) showed variable changes in expression, consistent with the 
idea of K27me3-independent regulation. Importantly, we observed high concordance in 
K27me3 deposition patterns between our mouse model and human tumors, particularly for 
genes under the regulatory control of PRC2, i.e. with high H3K27me3 in H3.3WT samples. To 
assess this, we classified human genes into four tiers based on H3K27me3 ChIP-Seq signal 
from a previously published dataset (Bender et al., 2013) (Figure 8C) and computed the 
proportion of overlap of each murine cluster with each of these four tiers (Figure 8D). Cluster 
M1, which has the highest level of K27me3, is strongly conserved, with 78% of genes falling 
into human cluster H1. This cluster contains the top homeobox genes deregulated in our 
dataset (i.e. ALX4, IRX2, SIX4, POU4F1, ISL2), as well as some of the Wnt pathway genes 
(i.e. WNT6 and WNT10A). M5, on the other hand, is depleted in K27me3 and shows 69% 
overlap with H3-H4. A general agreement is observed for all clusters with clear K27me3 
patterns (Figure 8D). As expected, clusters with less defined patterns show lower level of 
conservation (Figure S8C). 
Finally, we found rare instances of increased deposition of K27me3 despite the 
known inhibitory effects of the K27M mutation on the SET domain of EZH2. We detected a 
significant increase in K27me3 levels at the PDGFRA promoter in samples overexpressing 
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PDGFRA (Figure 8E). This indicates that a dynamic inhibitory feedback loop can be 
activated in response to exogenous overexpression of PDGFRA so as to repress its 
endogenous expression despite EZH2-inhibiting H3.3K27M. Active deposition of the 
H3K27me3 mark at selected sites remains possible in H3.3K27M cells (Figure 8E; Figure 
S8D), possibly by residual EZH2 activity, as recently suggested (Mohammad et al., 2017), or 
by continued activity of EZH1-containing complexes (Shen et al., 2008). 
 
Discussion 
Despite landmark discoveries in the genetics of rare cancers over the past 35 years, 
subsequent development of effective, targeted therapeutics has been rare. This is in part 
due to a lack of preclinical in vivo models that fully recapitulate the genetic and 
histopathological features of human tumors, thereby preventing the identification and 
validation of high-confidence treatment strategies. For pHGG in particular, there are 
currently no in vivo models simulating H3.3K27M-driven brain tumorigenesis. In this study, we 
generate a preclinical model of H3.3K27M oncohistone-driven neoplastic transformation, from 
which cells can be engrafted in recipient animals and that recapitulates histologic features of 
human pHGG.  
Tumorigenesis occurs only when H3.3K27M is introduced during development, as very 
early expression of this oncogene is lethal to mouse postzygotic cells whereas postnatal 
NPCs seem refractory to its oncogenic effects. Therefore, our data support an embryonic 
origin of H3.3K27M–driven tumors in mice, suggesting that the H3.3K27M mutation arises early 
in actively dividing neural precursors during CNS development where it produces a 
tumorigenic event by disrupting normal neurogenesis. This is supported by anecdotal 
findings of “pre”-DIPG tumors in very young children prior to clinical manifestations (Wright 
et al., 2015) and explains why initial attempts to model K27M-driven tumorigenesis 
postnatally using both Sleeping Beauty (our work) and the RCAS systems (Lewis et al., 
2013) were unsuccessful. Furthermore, our data implicate a specific window during NPC 
lineage specification for tumorigenesis to occur, as classical transgenic approaches using 
both the Nes and Gfap promoters in combination with Trp53 loss failed to induce tumors. 
Since we used a ubiquitous promoter to drive expression of H3.3K27M embryonically, the 
precise cell within the NPC lineage that can initiate tumorigenesis remains to be discovered. 
Interestingly, we show that NPCs in the forebrain and hindbrain are equally susceptible to 
neoplastic transformation upon concomitant introduction of H3.3K27M and its associated 
genetic changes. The tumors generated are clonal and derive from those stem cells 
expressing mutant H3.3 that were targeted during development using IUE. Hence, they 
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elucidate a possible mechanism by which H3.3K27M tumors initiate in human pHGG as well, 
i.e. during gestation.  
Our data suggest that the H3.3K27M requires only one additional genetic hit in the form 
of Trp53 loss to initiate tumorigenesis. While the process of transformation begins during 
development, it progresses slowly, taking 4 months in mice to advance to high-grade 
lesions. By 9 months, these lesions are spread throughout the rostrocaudal axis of the 
neocortex. It should be noted that although this model is the most representative of pHGG it 
still takes 4 months in mice. However, this incubation period is in accordance with most, if 
not all, other autochthonous models of medulloblastoma or adult glioma and may represent 
a fundamental aspect of brain cancer modeling in mice (Alcantara Llaguno et al., 2009; Hill 
et al., 2015).  
Addition of ATRX knockdown to H3.3K27M expression and Trp53 loss promotes focal 
or localized tumor formation, suggesting that ATRX loss diminishes the invasive potential of 
tumors. We have reported elsewhere that a large proportion of thalamic H3.3K27M tumors, 
and the majority of cortical H3.3G34R/V tumors, are more focal at initial presentation and 
display loss of ATRX (Fontebasso et al., 2014). This is in contrast to H3.3K27M DIPG where 
ATRX loss is rare (less than 10%) and subclonal (Nikbakht et al., 2016), potentially in 
accordance with our model. Furthermore, in adult HGG, ATRX loss associates with IDH 
mutations and TP53 loss and is also associated with improved prognosis (Pekmezci et al., 
2017; Wiestler et al., 2013), potentially due to better resection of focal tumors during surgery. 
On the other hand, the addition of WT PDGFRA overexpression significantly decreases 
tumor latency while drastically promoting invasion when co-expressed with H3.3K27M. 
H3.3K27M-bearing mouse tumors induced using piggyBac IUE recapitulate many 
aspects of human H3.3K27M pHGG. This includes 1) the characteristic invasive nature of 
these tumors, 2) migration along blood vessels, 3) colonization of the contralateral 
hemisphere, 4) upregulation of Olig2, an established diagnostic marker for H3.3K27M pHGG 
(Sturm et al., 2012), which positively correlates with the extent of invasion of transformed 
cells in vivo, and 5) scattered GFAP expression is in tumor samples.   
Molecular analysis of mouse datasets also showed that our model closely 
recapitulates human H3.3K27M mutant pHGG. Cross-species analysis of transcriptomic 
signatures and H3K27me3 deposition in mice and in human pHGG shows that H3.3K27M-
dependent transformation induces epigenetic and transcriptomic changes that are 
recapitulated in human tumors. Notably, our data indicate that de novo deposition of this 
mark is still possible despite the strong inhibitory effects of the H3.3K27M mutation on EZH2 
methyltransferase activity. Indeed, H3K27me3 is deposited at the endogenous PDGFRA 
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promoter to decrease PDGFRA expression in response to overexpression of ectopic 
PDGFRA. This negative feedback loop demonstrates a previously underappreciated 
dynamic deposition of H3K27me3 even in H3.3K27M mutant cells. The mechanisms behind 
this effect are unknown and are the subject of active investigations. 
In conclusion, we describe a faithful preclinical model of H3.3K27M-driven pHGG and 
provide a tool for studying molecular mechanisms underlying the transforming function of 
H3.3K27M. Our findings will enable the elucidation of developmental and tissue homeostasis 
mechanisms altered by H3.3K27M in pHGG, and promote discoveries targeting this 
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Figure 1. H3.3K27M expression and Trp53 loss are able to induce tumorigenesis in both 
cortex and hindbrain. (A) Schematic describing the in utero electroporation strategy used 
to deliver piggyBac transposable-H3.3K27M and Trp53 CRISPR/Cas9 (K27M-P) into lower 
rhombic lip NPCs in vivo. (B) Coronal section prepared from a K27M-P hindbrain 6 months 
after electroporation showing immunofluorescent detection of GFP, Ki67 and DAPI. Orange 
arrowhead indicates GFP+Ki67+ cells in the pons, shown at higher magnification on the right. 
Diffusely spreading GFP+Ki67+ cells are also seen migrating dorsally within the hindbrain. 
Scale bars represent 100 m (left) and 50 m (right). (C) Histopathological analysis of a 
hindbrain K27M-P tumor harboring Ki67+, Olig2+ and GFAP+ cells. Scale bars represent 0.5 
mm (left) and 75 m (right). (D) Coronal view of cortical K27M-P driven tumorigenesis. 8 
months following surgery GFP+Ki67+ cells are seen in cortical, ventral and contralateral 
locations (red arrows). Scale bars represent 1.5 mm. See also Figure S1 and Table S1.  
 
Figure 2. H3.3K27M expression and knockdown of ATRX and p53 in embryonic NPCs 
leads to tumorigenesis in postnatal animals. (A) Schematic describing the in utero 
electroporation strategy used to deliver piggyBac transposable-empty vector, H3.3WT or 
H3.3K27M along with ATRX shRNA and Trp53 CRISPR/Cas9 (EV/WT/K27M-AP) into cortical 
NPCs in vivo. (B) Validation of H3.3K27M-HA expression and knockdown of ATRX and p53 in 
ex vivo NPCs sorted and expanded 3 days following electroporation. (C) Coronal sections of 
EV-AP, WT-AP and two biological replicates of K27M-AP brains prepared 4 months 
following electroporation showing immunofluorescent detection of GFP, Ki67 and DAPI. 
GFP+Ki67+ cells in the cortex are indicated with an orange arrowhead, and contralaterally or 
ventrally migrating GFP+Ki67+ cells are indicated by the red arrows. Scale bars represent 1 
mm. (D) Immunofluorescent overlap between GFP+, Ki67+ and Nestin+ cells in EV-AP, WT-
AP and K27M-AP brains (two separate biological replicates shown for K27M-AP) 4 months 
following electroporation. Scale bars represent 50 m. (E) Quantification of GFP+Ki67+ cells 
in EV-AP, WT-AP and K27M-AP electroporated brains at 4 months. Data are represented as 
mean + SEM. (F) K27M-AP tumor appearance and immunofluorescence analysis, as 
depicted, at 9 months following electroporation. Scale bars represent 1.5 mm (left) and 50 
m (right). (G) Histology of K27M-AP tumors in comparison to a WT-AP electroporated 
brain. Scale bars represent 1 mm (top) and 100 m (bottom). *p<0.05, **p<0.01, 
****p<0.0001. See also Figure S2; Tables S1 and S2. 
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Figure 3. Addition of PDGFRAWT overexpression to H3.3K27M and ATRX/p53 KD results 
in shorter latency of tumorigenesis. (A) Schematic describing the in utero electroporation 
strategy used to deliver piggyBac transposable-empty vector, H3.3WT or H3.3K27M along with 
PDGFRAWT, ATRX shRNA and Trp53 CRISPR/Cas9 (EV/WT/K27M-APP) into cortical NPCs 
in vivo. (B) Validation of PDGFRAWT overexpression in ex vivo NPCs sorted and expanded 3 
days following electroporation. (C) Coronal sections of EV-APP, WT-APP and K27M-APP 
brains prepared 21 days and 4 months following electroporation showing immunofluorescent 
detection of GFP, TdTomato, Ki67 and DAPI. Scale bars represent 1.5 mm (multi-color 
panels) and 200 m (black-and-white panels). (D) Immunofluorescent overlap between 
GFP+, Ki67+ and PDGFRA in WT-APP and K27M-APP brains. Scale bars represent 50 m. 
(E) Quantification of GFP+Ki67+ cells in EV-APP, WT-APP and K27M-APP electroporated 
brains at 4 months. Data are represented as mean + SEM. (F) Comparison of Ki67 and 
Nestin immunofluorescence levels in WT-APP and K27M-APP at 9 months following 
surgery. Scale bars represent 50 m. (G) Left: low magnification view of K27M-APP tumors 
at 9 months. Right: immunofluorescence analysis of K27M-APP tumors, as depicted, 4 
months following surgery. Scale bars represent 1.5 mm (left) and 50 m (right). (H) Histology 
of K27M-APP tumors. Scale bars represent 100 m. *p<0.05, **p<0.01, ****p<0.0001. See 
also Figure S3 and Table S1. 
 
Figure 4. Allografted K27M-P, K27M-AP and K27M-APP tumor cells generate diffusely 
spreading Ki67+ lesions in NOD/SCID mice, demonstrating their transformed status. 
(A) Low magnification view of K27M-AP tumor cell detection using GFP 
immunohistochemistry in recipient cortex. Scale bars represent 1 mm. (B) Higher 
magnification views of GFP immunohistochemistry showing regions of dorsolateral and 
dorsomedial frontal cortex in K27M-P, K27M-AP and K27M-APP tumor cell-injected mice. 
Scale bars represent 100 m. (C) A small molecule library of 430 kinase inhibitors was 
applied to WT-AP, WT-APP, K27M-AP tumor and K27M-APP tumor cells, as well as EV 
control cells. Changes in viability are shown as a screen-wide image of z-scores (left) and a 
normal Q-Q plot (right). The normalized percent inhibition method was used to compare z-
scores of WT-AP and K27M-AP responses, as well as the z-scores of WT-APP and K27M-
APP responses. (D) Quantification of the effect of vacquinol-1 (left) and Akti-1/2 (right) on 
viability of K27M-AP and K27M-APP tumor cells, respectively, at a range of concentrations. 
Data are represented as mean + SEM. *p<0.05, **p<0.01, ****p<0.0001. See also Figure S4 
and Table S3. 
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Figure 5. K27M-AP and K27M-APP tumor cells have reduced K27me3 levels and 
migrate along blood vessels. (A) Acid-extracted histone preparations made from EV-AP, 
WT-AP and K27M-AP preneoplastic cells and K27M-P, K27M-AP and K27M-APP tumor 
cells were probed for K27me3, HA, K27ac, K36me3 and total H3 levels. (B) Left: 
representative images of K27me3 immunofluorescence in WT-AP and K27M-AP cells at 4 
months following electroporation. Right: representative images of K27me3 
immunofluorescence in WT-APP and K27M-APP cells at 21 days following electroporation. 
Cell bodies are highlighted within circles. Scale bars represent 50 m. (C) Quantification of 
K27me3 immunofluorescence signal intensity in WT-AP vs K27M-AP and WT-APP vs 
K27M-APP. Data are represented as mean + SEM. (D) Immunofluorescent detection of 
K27M-AP tumor cells, K27me3 and CD31+ blood vessels (indicated by white arrows). Scale 
bars represent 50 m. (E) Top panel: immunofluorescence of K27M-APP tumor cells 
expressing GFP and CD31+ blood vessels (indicated by white arrows). Bottom panel: 
immunofluorescence of K27me3 and HA signal (indicated by white arrows) in GFP+ K27M-
APP tumor cells. Scale bars represent 50 m. *p<0.05, **p<0.01, ****p<0.0001. See also 
Figure S5 and Table S4. 
 
Figure 6. Olig2 levels are increased in K27M-AP and K27M-APP tumor cells. (A) 
Representative images and quantification of Olig2+GFP+ cells in EV-AP, WT-AP and K27M-
AP brains at 4 months following electroporation. Scale bars represent 50 m. Data are 
represented as mean + SEM. (B) Representative images and quantification of Olig2+GFP+ 
cells in ipsilateral and contralateral cortical regions of K27M-APP brains at 4 months 
following electroporation. PDGFRA immunofluorescence is also shown. Scale bars 
represent 50 m. Data are represented as mean + SEM. (C) Relative invasion index of 
K27M-APP vs K27M-AP tumor cells. Data are represented as mean + SEM. (D) 
Quantification of the incidence of focal tumors correlating with ATRX loss. Chi-squared test. 
*p<0.05, **p<0.01, ****p<0.0001. See also Figure S6 and Table S1. 
 
Figure 7. H3.3K27M-dependent transformation induces transcriptomic changes that are 
recapitulated in human tumors. (A) Principal component analysis (PCA) of murine 
samples based on transcriptome-wide expression level data is shown. Curved arrow 
indicates a progression in global transcriptomic patterns from the untransformed to the 
transformed state. Control: EV-AP/EV-APP. WT: WT-AP. K27M: K27M-AP/K27M-APP. 
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K27M-T: K27M-AP T / K27M-APP T. (B) Two-dimensional visualization of the expression 
dataset was performed by t-SNE on the PCA space, using the first 50 PCs. 5,000 iterations 
were performed with perplexity=6 and theta=0.5. (C) t-SNE visualization of human normal 
brain, H3.3WT pediatric High Grade Glioma (pHGG) and H3.3K27M pHGG samples based on 
the expression of human orthologs of the murine K27M-T. 10,000 iterations were performed 
on the PCA space (first 50 PCs) with perplexity=2, theta=0. (D) Top: bubble plot 
summarizing the number of overlapping genes between the signatures derived from murine 
and human tumors. Bottom: Random expectations for the number of overlapping genes (N) 
with pGBM signatures were derived by iteratively sampling N genes from the human 
genome and computing the overlap with human tumor signatures (blue histograms, 10,000 
iterations). Red vertical lines correspond to the observed overlaps (K27M-T signature). P-
values indicate the probability of observing these overlaps by chance based on random 
expectations. (E) Gene expression changes (log2 FC) of the human orthologs of pathway-
specific gene subsets extracted from the murine K27M-T signature using functional 
annotation in H3.3K27M pHGG with respect to normal brain are shown. Red: K27M-T 
upregulated genes. Blue: K27M-T downregulated genes. Filed circles: statistically significant 
genes. Open circles: non-significant genes. Solid line: median log2 FC of significant genes. 
See also Figure S7; Tables S5, S6 and S7. 
 
Figure 8. K27M-induced alteration of genome-wide H3K27me3 deposition is captured 
by the mouse model. (A) ChIP-Rx Ratio: ratio of sequencing reads mapping to mouse 
genome and drosophila genome, normalized by input. (B) Heatmaps illustrating H3K27me3 
levels at transcription start sites (TSSs). H3K27me3 levels in regions of 10Kb surrounding 
TSSs (in rows) were normalized locally on a per-sample basis (in columns), and genes were 
subsequently clustered by k-means (k=12) based on average H3K27me3 levels in each 
sample. The five gene clusters most recapitulative of human K27M tumor H3K27me3 loss 
are shown, alongside the magnitude of changes in expression of their constituent genes 
(right). Only significant gene expression changes are reported, in the form of log2 fold-
change in K27M-T relative to baseline controls. H3.3 WT: EV-ctl, EV-PDGFRA. K27M: 
K27M-AP T /K27M-APP T. (C) Human genes were classified as in (B) into four tiers (k=4). 
K27me3 ChIP-Seq data was obtained from (Bender et al., 2013). A lower k was used since 
the lower coverage of this data set prevented a high resolution clustering of genes. Note that 
the number of annotated genes for mouse and human differ, and thus the heatmaps are not 
scaled to proportion. (D) Pairwise similarity matrix between murine (rows) and human 
(columns) gene clusters. Similarity was measured as the proportion of mouse genes with 
human orthologs present in each human cluster. (E) H3K27me3 levels found at the loci of 
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selected genes showing increased (Pdgfra, Satb2) or decreased (Wnt6, Wnt10a, Tacr3) 
mark deposition. Coverage is normalized across all samples. See also Figure S8 and Table 
S8. 
 
CONTACT FOR REAGENT AND RESOURCE SHARING 
Further information and requests for resources and reagents should be directed to and will 
be fulfilled by the Lead Contact Paolo Salomoni (p.salomoni@ucl.ac.uk). 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
Mice 
All mice were housed, bred and subjected to listed procedures according to institutional, 
Animal Welfare and Ethical Review Body (AWERB) and UK Home Office guidelines (Project 
licence 70/8240, 70/7428 and 80/2325). Female and male C57BL/6J mice were used for in 
utero electroporations. Female and male NOD SCID mice were used for allotransplantation 
experiments. Mice were monitored daily for neurological symptoms of brain tumors: weight 
loss, epilepsy, altered gait, lethargy; and euthanized immediately when recommended by 




The piggyBac donor and helper vector system was used to transduce NPCs in utero as 
described previously (Chen and LoTurco, 2012).  CAG-PBase and PBCAG-GFP were a kind 
gift from F. Chen and J. LoTurco. PBCAG-H3.3WTHA-2A-GFP and PBCAG-H3.3K27MHA-2A-
GFP were generated by linearising PBCAG-GFP using EcoRI/NotI and using HIFI Gibson 
assembly (NEB) to insert cDNA encoding C-terminal HA-tagged Drosophila His3.3A (a 
highly conserved ortholog of mammalian H3f3a) followed by a P2A self-cleaving linker and 
the EGFP sequence. K27M mutants were generated using Quikchange Lightning site-
directed mutagenesis (Agilent). The stop codon was removed following H3.3HA to allow for 
polycistronic mRNA translation. Two ATRX shRNA vectors with equivalent knockdown 
efficiencies were obtained by cloning the following sequences into the short hairpin RNA 
construct PBmU6pro (kind gift from J. Loturco), cut with BbsI/XbaI: 5’-
TTCATTTACATTCTCATCCGTG-3’; 5’-TCATTTACATTCTCATCCG-3’. A control (ctl) 
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shRNA vector was constructed using a scrambled shRNA sequence (5’-
CCAACTCTTGTTTCAGCCG-3’) lacking homology to any known mouse and human genes 
as described previously (Singh et al., 2010). CRISPR/Cas9 pX330 vectors containing 
negative control (5’-GCGACCAATACGCGAACGTC-3’) or Trp53-targeting gRNA (5’-
ACAGCCATCACCTCACTGCA-3’) sequences were a kind gift from J. Gronych (Zuckermann 
et al., 2015). PBCAG-PDGFRA was constructed by removing EGFP from PBCAG-GFP 
using AgeI/NotI to remove problematic restriction sites, blunt-ligating and then inserting 
PCR-amplified murine mPDGFRA from pcDNA5FRT-EF-Pdgfralpha-EGFPN (L. Pederson, 
Addgene #66787) into the KPnI/XmaI-digested vector. The PBCAG-PDGFRA-PQR-
tdTomato vector was constructed by inserting a self-cleaving PQR sequence into AgeI/NotI-
digested PBCAG-GFP, then inserting the tdTomato-encoding sequence (M. Davidson and 
R. Tsien, Addgene #54642) downstream from the PQR using NheI/NotI and finally inserting 
the mPDGFRA sequence upstream from the PQR using KPnI/XmaI. The stop codon was 
removed following mPDGFRA to allow for polycistronic mRNA translation.  
In Utero Electroporation 
In utero electroporation was performed using sterile technique on isoflurane/oxygen-
anesthetized pregnant females at E12.5 (hindbrain) or E13.5 (cortex) as described 
previously (Nitarska et al., 2016). Analgesic support was also provided pre-emptively 
(subcutaneous delivery of Vetergesic and Carpofen at 0.1 mg/kg and 5 mg/kg, respectively). 
Uterine horns were exposed through a 1 cm incision and individual embryos were digitally 
manipulated into the correct orientation for intraventricular injection. Pulled borosilicate 
capillaries were loaded with endotoxin-free DNA and Fast Green dye (0.05%, Sigma) for 
visualisation, and a microinjector (Eppendorf) was used to inject either the lateral or fourth 
ventricles with the DNA-dye mixture. 3-5 plasmids were injected simultaneously, each at a 
final concentration of 2 g/l and 1-2 l of total solution was injected per embryo. DNA was 
electroporated into cortical neural progenitors using 5 mm tweezertrodes (BTX), or into lower 
rhombic lip progenitors using 3 mm tweezertrodes, applying 5 square pulses at 35 V, 50 ms 
each with 950 ms intervals. The embryos were returned into the abdominal cavity, the 
muscle and skin were sutured and the animal was monitored until fully recovered from the 
procedure.  
Ex vivo NPC Isolation and Culture 
Animals were euthanized by CO2 exposure and/or cervical dislocation and cortices were 
rapidly dissected in ice-cold dissociation medium containing: 20 mM glucose, 81.8 mM 
Na2SO4, 30 mM K2SO4, 5.8 mM MgCl2, 250 M CaCl2, 1 mM HEPES, 160 M NaOH, 0.8 
mM kynurenic acid, 50 M D-APV, 100 U/mL penicillin, 100 g/mL streptomycin, 5 g/ml 
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plasmocin and 100 g/ml primocin. GFP+ regions were microdissected under an 
epifluorescence stereomicroscope in the same medium and enzymatically digested into a 
single-cell suspension using the Papain Dissociation System (Worthington Biochemicals) 
followed by mechanical trituration through a series of fire-polished Pasteur pipettes. The 
dissociated cell solution was then separated on an OptiPrep density gradient to remove 
debris and GFP+TdTomato+ cells were sorted using a FACSAria III or LSRFortessa X-20 
(BD Biosciences) into Hibernate-E media (Life Technologies) containing 2% B-27, 2 mM 
Glutamax, 0.8 mM kynurenic acid, 50 M D-APV, 100 U/mL penicillin, 100 g/mL 
streptomycin, 5 g/ml plasmocin and 100 g/ml primocin.  Sorted cells were plated into 
NeuroCult NSC proliferation media (STEMCELL Technologies) containing 10 ng/ml of both 
epidermal growth factor (EGF, Peprotech) and basic fibroblast growth factor (bFGF, 
Peprotech) in laminin-coated culture vessels (Sigma).  
Western Blot Analyses 
Cells were scraped on ice in lysis buffer containing 50 mM Tris (pH 7.5), 0.5% Triton-X, 150 
mM NaCl, 1 mM EDTA, 1 mM PMSF and 1X Halt protease and phosphatase inhibitor 
(Thermo Fisher Scientific). Lysates were rotated for 30 min, sonicated briefly, cleared by 
centrifugation at 13000 rpm for 10 min, quantified using the BCA assay and then boiled in 
Laemmli buffer for 3 min. SDS-PAGE was carried out with 20 g of protein per sample, 
transferred to nitrocellulose and then blocked in 5% skimmed milk or BSA dissolved in PBS-
Tween or TBS-Tween (0.1% Tween), respectively, for 1 hr at RT. Membranes were 
incubated with primary antibodies at 4°C overnight, washed in PBS-Tween/TBS-Tween and 
then incubated with IRDye-conjugated anti-rabbit and anti-mouse secondary antibodies (LI-
COR) for 1 hr at RT. Signal detection and quantification was performed using an Odyssey 
infrared detection instrument (LI-COR) and immunoblots were performed at least thrice to 
confirm reproducibility.  
Nuclear extraction and co-immunoprecipitation was performed using the Universal Magnetic 
Co-IP kit (Active Motif). Briefly, cells were lysed in a hypotonic solution and nuclear extracts 
were prepared using an enzymatic shearing cocktail designed to preserve complexes of 
DNA-binding proteins. Nuclear extracts were incubated with primary antibody at 4°C 
overnight after which magnetized Protein G beads were added to the mixture for a further 4 
hr. The beads were then washed several times before boiling in reducing buffer and SDS-
PAGE analysis.  
Histone acid extraction was performed as previously described (Shechter et al., 2007). 
Briefly, cell pellets were lysed in hypotonic buffer containing 10 mM Tris-Cl (pH 8.0), 1 mM 
KCl, 1.5 mM MgCl2, 1 mM DTT and 1X Halt protein and phosphatase inhibitor, the nuclei 
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were resuspended in 0.4 N H2SO4 and incubated overnight to solubilise histones and then 
precipitated using trichloroacetic acid. Precipitated histones were washed in acetone and 
resuspended in ddH2O, quantified and then boiled in Laemmli buffer prior to SDS-PAGE 
analysis.  
RNA Extraction and qPCR 
Total RNA was extracted using the RNeasy Plus Mini kit (Qiagen). RNA was quantified using 
an ND-1000 spectrophotomoter (NanoDrop) or on a 2100 Bioanalyzer (Agilent). cDNA was 
prepared using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Real-
Time PCR was performed using Fast SYBR Green Master Mix (Applied Biosystems). 
Relative expression levels were normalised to B2m within samples and calculated using 2-
Ct method as previously described (Livak and Schmittgen 2001).  
Allograft of Tumor Cells 
15 l of 1x106 tumor cells were injected into the left striatum of adult NOD SCID mice 
(bregma, 1.5 mm lateral, 2 mm deep), using a 22 G needle and a 25 l Hamilton syringe. 
Mice were examined twice weekly for the development of neurological signs of intracranial 
pressure before euthanasia. 
Immunostaining 
P21 - 12 month old mice under terminal anaesthesia were transcardially perfused with ice-
cold PBS followed by ice-cold 4% paraformaldehyde. Brains were dissected and postfixed in 
4% paraformaldehyde overnight before sectioning on a VF-700 compresstome (Precisionary 
Instruments) into 50-100 m thick free-floating sections. For embryonic mice, brains were 
rapidly dissected in ice-cold PBS and drop-fixed in 4% paraformaldehyde overnight before 
transferring to a 30% sucrose-PBS solution. After complete permeation with sucrose 
solution, brains were frozen in O.C.T. (Sakura) on liquid nitrogen-cooled isopentane and 
sectioned on a Leica 3050S cryostat (Leica Biosystems) into 20 m thick slide-mounted 
sections.  
For immunofluorescence, free-floating or slide-mounted sections were incubated in a 
blocking solution (10% goat or donkey serum, 3% BSA, 0.3% Triton-X in PBS) for 1 hr at RT 
and then incubated with primary antibodies at 4°C overnight. Sections were washed in PBS-
Tween (0.05%) before addition of Alexa Fluor- or DyLight-conjugated secondary antibodies 
in blocking solution for 1 hr at RT. Following washing, sections were mounted in ProLong 
Gold mounting reagent containing DAPI (Thermo Fisher Scientific) and imaged on a 
confocal microscope (Zeiss LSM 700/880). 
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For histological analysis of tumors, mice were perfused with ice-cold 10% formalin, brains 
were dissected and embedded in paraffin, cut into 3 m sections and processed for 
haematoxylin-eosin (HE) staining. Immunohistological detection of various antigens was 
performed on the Ventana Discovery automated staining platform (Ventana Medical 
Systems) using biotin-free secondary antibodies coupled to streptavidin-horseradish 
peroxidase and diaminobenzidine as a chromogen. Slides were digitized on a Leica SCN400 
scanner and viewed/exported using Slidepath software (Leica Biosystems). 
Cell Counts and Image Quantification 
GFP+Ki67+Nestin+ and GFP+Olig2+ cells in cortex and striatum were manually counted using 
the multi-point tool in ImageJ in a blinded manner. GFP+ neurons, astrocytes and 
oligodendrocytes were identified using both morphology and cell type-specific markers 
(neurons: NeuN; astrocytes: GFAP/glutamine synthetase; oligodrendrocytes: 
Olig2/PDGFRA) and manually counted in a similar manner. Intensity of H3K27me3 
fluorescence signal in HA+ cells was quantified using both ImageJ and Metamorph software 
(Molecular Devices). 2-4 single-plane confocal images with a z-step of 2 m were combined 
for fluorescence intensity analysis (total depth less than 10 m). All cell counting and 
fluorescent intensity analyses were carried out on images from a minimum of 3 mice per 
condition.  
RNA-sequencing 
Total RNA was extracted from cell pellets and mouse tumors using the AllPrep 
DNA/RNA/miRNA Universal Kit (Qiagen) according to instructions from the manufacturer. 
Library preparation was performed with ribosomal RNA (rRNA) depletion according to 
instructions from the manufacturer (Epicentre) to achieve greater coverage of mRNA and 
other long non-coding transcripts. Paired-end sequencing was performed on the Illumina 
HiSeq 2500 platform. 
Exome-sequencing 
Genomic DNA was extracted from cell pellets and frozen tumor tissue and the Agilent 
SureSelect Reagent Exome kit (Agilent) was used to prepare DNA libraries according to the 
manufacturer’s instructions. Sequencing was performed on Illumina HiSeq 2000 using rapid-
run mode with 100 bp paired-end reads. 
Kinase inhibitor screening assay 
The compounds from the Life Kinase Inhibitor Library-Z198511 (Selleckchem) were 
dispensed into 96-well plates at a final concentration of 10M, using an acoustic liquid 
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handler Echo 550 (Labcyte Inc. Sunnyvale, CA). DMSO was used at the final concentration 
of 0.001% and celecoxib (positive control) at the final concentration of 20M. Plates were 
prepared in triplicate. Cells were seeded into the plates at density of 5000 to 7500 cells/well 
in volume of 90l/well using a multiflo dispenser (Biotek) at low speed. Cells were then 
incubated at 37C, 5% CO2 for a period of 72 hr. After the exposure period, 10% final 
PrestoBlue (Life Technologies) was added to each well and the plates were returned to the 
incubator for 6 hr. The fluorescence intensity was measured using a multiwell plate reader 
(Envision, Perkin Elmer) at excitation 544nm and emission 620nm. The celHTS2 software 
package was used for drug screen analysis and generation of z-scores (Boutros et al., 
2006). 
ChIP-sequencing 
Cells were fixed with 1% formaldehyde (Sigma). Fixed cell preparations were washed, 
pelleted and stored at -80°C. Sonication of lysed nuclei (lysed in a buffer containing 1% 
SDS) was performed on a BioRuptor UCD-300 for 60 cycles, 10s on 20s off, centrifuged 
every 15 cycles, chilled by 4°C water cooler. Samples were checked for sonication efficiency 
using the criteria of 150-500bp by gel electrophoresis. After the sonication, the chromatin 
was diluted to reduce SDS level to 0.1% and before the ChIP reaction 2% of sonicated 
drosophila S2 cell chromatin was spiked into the samples for quantification of total levels of 
histone mark after sequencing (see below). 
The ChIP reaction was performed on a Diagenode SX-8G IP-Star Compact using Diagenode 
automated Ideal ChIP-seq Kit. 25l Protein A beads were washed and then incubated with 
5g of H3K27me3 antibody (Cell Signaling Technologies, #9733) and 2 million cells of 
sonicated cell lysate combined with protease inhibitors for 10 hr, followed by 20 min wash 
cycle with provided wash buffers. Reverse cross linking took place on a heat block at 65°C 
for 4 hr. ChIP samples were then treated with 2l RNase Cocktail at 65°C for 30 min 
followed by 2l Proteinase K at 65°C for 30 min. Samples were then purified with QIAGEN 
MiniElute PCR purification kit as per manufacturers’ protocol. In parallel, input samples 
(chromatin from about 50,000 cells) were reverse crosslinked and DNA was isolated 
following the same protocol.  
Library preparation was carried out using Kapa HTP Illumina library preparation reagents. 
Briefly, 25l of ChIP sample was incubated with 45l end repair mix at 20°C for 30 min 
followed by Ampure XP bead purification. A tailing: bead bound sample was incubated with 
50l buffer enzyme mix for 30°C 30 min, followed by PEG/NaCl purification. Adaptor ligation: 
bead bound sample was incubated with 45l buffer enzyme mix and 5l of different TruSeq 
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DNA adapters (Illumina) for each sample, for 20°C 15 min, followed by PEG/NaCl 
purification (twice). Library enrichment: 12 cycles of PCR amplification. Size selection was 
performed after PCR using a 0.6x/0.8x ratio of Ampure XP beads (double size selection) set 
to collect 250-450bp fragments. 
ChIP libraries were sequenced using Illumina HiSeq 2000 at 50bp SE reads. 
Bioinformatics –RNA-Seq Data Processing 
RNA sequencing reads were trimmed using Trimmomatic (v0.32) (Bolger et al., 2014) , 
removing adaptor and other Illumina-specific sequences as well as the first four bases from 
the start of each read, and low-quality bases at the end of each read, using a 4bp sliding 
window to trim where average window quality fell below 30 (phred33 < 30). In addition, an 
additional 3bp was clipped from the start and end of a read if found of low quality. Trimmed 
reads < 30 bp were discarded. The resulting clean set of reads were then aligned to the 
reference genomes using STAR (v2.3.0e) (Dobin et al., 2013) with default parameters. 
Reads mapping to more than 10 locations in the genome (MAPQ < 1) were discarded. The 
reference genome build used was hg19 (GRCh37) for human samples and mm10 
(GRCm38) for mouse samples.  
Gene expression levels were estimated by quantifying uniquely mapped reads to exonic 
regions (the maximal genomic locus of each gene and its known isoforms) using 
featureCounts (v1.4.4) (Liao et al., 2014) and the Ensembl gene annotation set. 
Normalization (mean of ratios) and variance-stabilized transformation of the data were 
performed using DESeq2 (Love et al., 2014). Multiple control metrics were obtained using 
FASTQC (v0.11.2), samtools (v0.1.19) (Li et al., 2009), BEDtools (v2.17.0) (Quinlan and 
Hall, 2010) and custom scripts. For visualization, normalized Bigwig tracks were generated 
using BEDtools and UCSC tools. Integrative Genomic Viewer (Thorvaldsdóttir et al., 2013) 
was used for data visualization.  
Bioinformatics –RNA-Seq Clustering 
Global changes in expression levels were evaluated using the t-Stochastic Neighbor 
Embedding (t-SNE; perplexity=6; N=5000 iterations; algorithm applied to the PCA space by 
taking the first 50 PCs) (Garcia-Alonso et al., 2014) and principal component analysis (PCA) 
dimensionality-reduction techniques on normalized expression data coupled with variance-
stabilized transformation (DESeq2) (Love et al., 2014)). 
Bioinformatics –Gene Signatures 
Differential expression analysis was performed using DESeq2 (Love et al., 2014). 
Statistically significant (adjusted p value ≤ 0.05) genes with large expression changes 
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(absolute fold change ≥ 2) that are expressed above a threshold (average normalized 
expression across samples ≥ 50) were identified for all mouse models and human samples. 
Gene signatures for each of the murine models (i.e. K27M-AP T and K27M-APP T) were 
derived by differential expression of each relative to baseline controls (EV ctl) and 
subsequent removal of genes present in the WT-AP signature (i.e. differentially expressed 
genes between WT-AP and baseline controls, representing genes deregulated simply by 
overexpression of H3.3 and knockdown of ATRX/p53). Extended gene signatures for K27M 
tumors (K27M-T, pooling together K27M-AP T and K27M-APP T) were derived by differential 
expression relative to extended controls (i.e. EV ctl and EV-PDGFRA). Similarly, gene 
signatures corresponding to human H3.3WT pHGG and H3.3K27M pHGG were derived by 
differential expression relative to tumor-matched normal brain controls (NB). 
Each of the gene signatures was functionally annotated using DAVID (Huang et al., 2007), 
computing their enrichments against a background set of genes. Background genes for 
mouse signatures were defined as genes expressed across all mouse samples (i.e. in the 
upper 3 quartiles of expression for at least one sample in the entire dataset). Background 
genes for human signatures were similarly obtained. Specific signatures corresponding to 
defined pathways of interest (e.g. K27M-T DNA-binding) were then obtained by subsetting 
the corresponding genes from each signature based on functional annotations.  
Bioinformatics –Comparison of Human and Mouse Expression Data 
To assess the relevance of the genes identified in our mouse cell and tumor models in 
human patient data, we employed three distinct approaches. 
(1) Unsupervised clustering of human samples based on expression levels of human 
orthologs of genes belonging to each murine signature using the t-SNE (perplexity=2; 
N=10000 iterations; using the first 50 PCs of expression data) and PCA dimensionality-
reduction techniques; exact, case insensitive match of their corresponding HGNC symbols 
(i.e. murine Sox10 to human SOX10) was required (Figure 7C). 
(2) Computation of overlaps of genes (exact, case insensitive match of HGNC symbols as 
well as agreeing directions of change in expression; Figure 7D and Figure S8D). In order to 
assess the significance of the reported overlaps in each human-murine signature 
comparison, we computed an empirical p value for the reported overlap in each comparison. 
For each comparison, we obtained a null distribution of overlaps by repeatedly resampling 
(N=10,000 iterations) murine signatures of the same length as the original murine signature, 
computing for each the number of overlapping gene orthologs in the human signature. The 
murine genes available for resampling were limited to those that are expressed in 
corresponding murine comparison by filtering out those with a null fold-change. 
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(3) Projection of murine signatures across human samples using single sample gene set 
enrichment analysis (ssGSEA) as described before (Barbie et al., 2009). Briefly, a score is 
defined to represent the degree of enrichment of a given gene set in a sample: gene 
expression values are rank-normalized for each sample, and an enrichment score is 
produced using the Empirical Cumulative Distribution Function (ECDF) of genes, with the 
final score obtained by integrating the difference between a weighted ECDF of genes in the 
signature and the ECDF of the remaining genes. This calculation is computed for each 
signature and each sample, using the ssGSEAProjection (v6) module of the GenePattern 
suite (Kuehn et al., 2008). Genes in the murine signatures were converted to their human 
orthologs using biomaRt (v2.26.1) (Smedley et al., 2015) prior to ssGSEA enrichment 
analysis (Figure S8E). 
Bioinformatics –H3K27me3 ChIP-Seq Data Processing 
ChIP-seq reads were aligned to the mouse reference genome build mm10 (GRCm38) using 
bwa (v0.7.10-r789) (Jo and Koh, 2015) with default settings. BigWig tracks were generated 
for each sample, with coverage scaled according to ChIP-Rx ratio (Orlando et al., 2014). The 
tracks were then visualized in the Integrative Genomics Viewer (Thorvaldsdóttir et al., 2013). 
Bioinformatics –Calculation of ChIP-Rx Ratio 
The spiked-in drosophila chromatin was used for quantification of histone mark, as described 
in Orlando et al., 2014 (Orlando et al., 2014). After sequencing, the reads were aligned to 
mouse and drosophila genomes, then the number of reads mapping to each genome (from 
H3K27me3 and input samples) were used to compute the relative levels of histone mark 
using the following formula for each sample: 
 
An in-depth calculation of the ChIP-Rx ratio is provided in Table S8. 
Bioinformatics –H3K27me3 ChIP-Seq Clustering 
H3K27me3-level based clustering of genes was performed using ngs.plot (v2.61) (Shen et 
al., 2014). Gene intervals were obtained from the Ensembl gene annotation set release 75 
for the mouse genome build mm10 (GRCm38). Intervals extending from 10kb upstream to 
10kb downstream of the transcription start sites (TSS) of all genes were considered in the 
summarization of H3K27me3 levels for each gene. Intervals were binned into 100bp 
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windows, and ChIP-Seq reads normalized locally on a per-sample basis into Z-scores, 
considering both IP and input reads. Genes were then clustered by k-means (k=12) based 
on average perigenic H3K27me3 levels in each sample. 
Bioinformatics –Comparison of Human and Mouse H3K27me3 Data 
In order to assess the agreement of H3K27me3 distribution in genic regions between our 
mouse model and human patient data, we obtained H3K27me3 ChIP-seq data for H3.3WT 
and H3.3K27M pHGG through European Genome-phenome Archive accession number 
EGAS00001000578 (Bender et al., 2013). We clustered these human tumor-derived 
H3K27me3 data into k=4 classes based on average perigenic H3K27me3 levels using the 
same method as mentioned above, but with gene intervals obtained from the Ensembl gene 
annotation set release 75 for the human genome build hg19 (GRCh37). 
Next, we estimated agreement between clusters found in human and mouse data by 
computing the proportion of genes in each mouse cluster that have orthologs in each of the 
4 human clusters. The mouse-to-human ortholog association map were again obtained 
using the R Bioconductor package biomaRt (v2.26.1) (Smedley et al., 2015). Finally, we 
considered only one-to-one associations in order to obtain a conservative measure of 
agreement between cross-species H3K27me3 cluster gene assignment. 
Bioinformatics –De Novo Deposition of H3K27me3 
Peaks were called on each murine ChIP-seq sample using the callpeak function of MACS2 
(v2.1.1.20160309) (Zhang et al., 2008) with the “broad” and “nomodel” flags as well as a 
default FDR cutoff of 0.05. Both IP and input reads were considered for peak calling and the 
mouse genome build mm10 (GRCm38) was used as a reference genome. Differential 
binding analysis was then performed in different groupings of H3.3K27M samples (all K27M 
samples, K27M tumors-only, and individual tumors) relative to H3.3WT (EV-ctl, EV-PDGFRA, 
WT-AP, WT-APP) samples based on the peak calls using the R Bioconductor package 
DiffBind (v2.5.4), which was modified to allow libraries to be normalized according to their 
respective ChIP-Rx scaling factors. Peaks significantly increased (FDR < 0.05) in tumor 
samples with respect to controls were inspected manually using IGV and reported in Figure 
S9D. 
Bioinformatics –Whole Exome-Seq Data Processing 
Exome sequencing reads were processed using the same approach as for RNA-seq with the 
exception that the first 4 bases at the start of each read are retained. The resulting reads 
were then aligned to the mm10 (GRCm38) reference genome using BWA-MEM v0.7.13 (Li 
and Durbin, 2010) using default parameters.  
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Bioinformatics –WES and RNA-Seq Variant Calling 
The split’N’Trim function of the Genome Analysis Toolkit (GATK) (v3.2-2) (Van der Auwera 
et al., 2013) was used to split reads that have introns and reassign the mapping quality from 
255 to 60. The IndelRealigner function of GATK was then used to realign indels. Duplicate 
reads were marked using the Picard toolset (v1.118). Variants are called using the mpileup 
function of samtools (v0.1.19) (Li et al., 2009) and using Annovar (February 2, 2016 version) 
(Wang et al., 2010) over the mm10 refGene annotation.  
For WES samples, positions where coverage is greater than 1000 were considered to be 
sequencing artefacts and thus ignored. Finally, we applied multiple levels of filters to remove 
likely false positive variant calls on WES or RNA-seq samples, retaining only variants with 
coverage ≥ 10 reads, alternative nucleotide count ≥ 3, SNV ratio ≥ 5%, indel ratio ≥ 15%, 
variant quality ≥ and mapping quality ≥ 15.  
Bioinformatics –CRISPR Off-Target and Spontaneous SNV Analysis 
In order to evaluate the presence of potential off-target effects of the CRISPR construct 
targeting Trp53 (Zuckermann et al., 2015), we obtained a list of 40 possible off-targets using 
the Cas-OFFinder web tool (Bae et al., 2014) based on the gDNA sequence, allowing up to 
3 mismatches of the gDNA sequence. We found that none of the potential off-target genomic 
locations harbored variants in K27M-P T RNA-seq sample that were not also found in the 
Trp53+/+ control samples (EV-ctl and EV-PDGFRA). We performed a similar analysis in order 
to detect the occurrence of spontaneous SNVs, where we report variants occurring in exonic 
regions that are found in the K27M-P T RNA-seq sample but not in the Trp53+/+ control 
samples (prior to variant filtration; EV-ctl and EV-PDGFRA). Additionally, we provide the 
number tumor Trp53-/- K27M that also habor these variants (after filtration). 
Bioinformatics –Clonality Analysis 
From the filtered list of putative SNVs obtained for each of the 10 WES samples derived 
from spatial biopsies of one K27M-AP tumour, we discarded all the but the most reliable 
SNVs, that is, non-synonymous variants occurring in exonic regions. Using PyClone 
(v0.13.0) (DOI:10.1038/nmeth.2883) to infer the clonal structure of the tumor, we obtained a 
final set of 336 variants that were clustered into 10 clusters. The number of clusters was 
reduced to 7 after discarding the clusters consisting of a single SNV (Figure S5). 
To assess the similarity of the complete mutational landscape of the tumor beyond that of 
only non-synonymous exonic variants, we determined a complete set of genomic positions 
harboring variants in at least one of the 10 biopsies (i.e. union of the good quality variants) 
and then calculated the variant allele frequency (VAF) of each site for each biopsy, 
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discarding the indels in the process. Next, to obtain a measure of similarity between 
samples, we calculated for each pair i, j (respectively rows and columns in Table S4) of 
biopsies the proportion of good quality variants in the i-th biopsy that were also present in 
the j-th biopsy with VAF > 0%. 
QUANTIFICATION AND STATISTICAL ANALYSIS 
All values and graphs are expressed as mean + SEM (standard error of the mean) and 
statistical analyses were performed using unpaired two-tailed t tests, ordinary one-way 
ANOVA followed by Tukey post hoc analysis or the Chi-squared test (GraphPad Prism). A 
statistically significant difference was indicated by a p value less than 0.05. 
 
DATA AND SOFTWARE AVAILABILITY 
All sequencing data have been deposited on GEO (accession number GSE95169) and can 




Table S2. Related to Figure 2. CRISPR off-target and spontaneous SNV analysis. 
 
Table S3. Related to Figure 4. List of drugs identified in the kinase inhibitor library 
screen and their z-scores. 
 
Table S4. Related to Figure 5. Concordance matrix of SNVs. 
 
Table S5. Related to Figure 7. Gene signatures. 
 
Table S6. Related to Figure 7. Signature overlaps. 
 
Table S7. Related to Figure 7. Functional annotations. 
 






 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
Chicken polyclonal anti-GFP Abcam Cat# ab13970; 
RRID: AB_300798 
Mouse monoclonal anti-HA Santa Cruz 
Biotechnology 
Cat# sc-7392; RRID: 
AB_627809   
Rabbit polyclonal anti-HA Santa Cruz 
Biotechnology 
Cat# sc-805; RRID: 
AB_631618 
Rabbit polyclonal anti-H3.3 EMD Millipore Cat# 09-838; RRID: 
AB_10845793 
Rabbit monoclonal anti-H3.3 K27M RevMAb Biosciences Cat# 31-1175-00  
Rabbit monoclonal anti-H3.3 G34R RevMAb Biosciences Cat# 31-1120-00 




Rabbit polyclonal anti-p53 Novocastra Cat# NCL-p53-
CM5p; RRID: 
AB_563933 




Mouse monoclonal anti--Tubulin Sigma Cat# T5168; RRID: 
AB_477579 
Rabbit monoclonal anti-Ki67 Abcam Cat# ab16667; 
RRID: AB_302459 
Mouse monoclonal anti-Nestin EMD Millipore Cat# MAB353; 
RRID: AB_94911 
Mouse monoclonal anti-GFAP EMD Millipore Cat# MAB360; 
RRID: AB_2275415 
Goat polyclonal anti-GFAP Abcam Cat# ab53554; 
RRID: AB_880202 
Rabbit monoclonal anti-NeuN Abcam Cat# ab177487; 
RRID: AB_2532109 
Rabbit polyclonal anti-H3K27me3 EMD Millipore Cat# 07-449; RRID: 
AB_310624 
Rabbit monoclonal anti-H3K27me3 Cell Signaling 
Technology 
Cat# 9733; RRID: 
AB_2616029 
Rabbit polyclonal anti-H3K27ac Abcam Cat# ab9060; RRID: 
AB_569354 
Rabbit polyclonal anti-H3K36me3 Abcam Cat# ab4729; RRID: 
AB_2118291 
Rabbit polyclonal anti-H3 Abcam Cat# ab1791; RRID: 
AB_302613 
Rabbit polyclonal anti-Olig2 EMD Millipore Cat# AB9610; RRID: 
AB_570666  
Goat polyclonal anti-PDGFRA R&D Systems Cat# AF1062; RRID: 
AB_2236897 
Rabbit polyclonal anti-MBP EMD Millipore Cat# AB980; RRID: 
AB_92396 
Rat monoclonal anti-CD31 BD Pharmingen Cat# 550274; RRID: 
AB_393571 
Rabbit polyclonal anti-DAXX Santa Cruz 
Biotechnology 




 See Table S1 This paper N/A 
Chemicals, Peptides, and Recombinant Proteins 
Vetergesic (Buprenorphine) National Veterinary 
Supplies 
Cat# 028745 
Rimadyl (Carprofen) National Veterinary 
Supplies 
Cat# 291729 
Marcain National Veterinary 
Supplies 
Cat# 178433 
Isoflurane National Veterinary 
Supplies 
Cat# 115095 
Kinase Inhibitor Library Selleckchem Cat# L1200 
NeuroCult Proliferation Kit STEMCELL 
Technologies 
Cat# 05702 
bFGF Peprotech Cat# 100-18B 
EGF Peprotech Cat# AF-100-15 
PDGF-AA Peprotech Cat# 500-P46 
Critical Commercial Assays 
Biocoat Matrigel Invasion Chambers Corning Cat# 354480 
Cell Culture Insert with 8.0mm PET Membrane Falcon Cat# 353097 
QuikChange Lightning Site-Directed Mutagenesis Kit  Agilent Cat# 210518 
AllPrep DNA/RNA/miRNA Universal Kit Qiagen Cat# 80224 
RNeasy Plus Mini Kit Qiagen Cat# 74134 
High Capacity cDNA Reverse Transcription Kit Applied Biosystems Cat# 4368814 
SYBR Green Master Mix Applied Biosystems Cat# 4385612 
TruSeq Stranded Total RNA Library Prep Kit with Ribo-
Zero Human/Mouse/Rat 
Illumina Cat# RS-122-2201 
iDeal ChIP-seq Kit for Histones Diagenode Cat# C01010051 
Kapa HTP Library Preparation Kit Illumina Platforms Roche Cat# 07961901001 
Deposited Data 
Raw and processed data This paper GEO: GSE95169 
Experimental Models: Cell Lines 
Mouse ex vivo NPCs: EV-GFP; control shRNA; control 
CRISPR 
This paper N/A 
Mouse ex vivo NPCs: EV-GFP; ATRX shRNA; Trp53 
CRISPR 
This paper N/A 
Mouse ex vivo NPCs: WT H3.3-GFP; ATRX shRNA; 
Trp53 CRISPR 
This paper N/A 
Mouse ex vivo NPCs: K27M H3.3-GFP; ATRX shRNA; 
Trp53 CRISPR 
This paper N/A 
Mouse ex vivo NPCs: EV-GFP; control shRNA; control 
CRISPR; PDGFRA 
This paper N/A 
Mouse ex vivo NPCs: EV-GFP; ATRX shRNA; Trp53 
CRISPR; PDGFRA 
This paper N/A 
Mouse ex vivo NPCs: WT H3.3-GFP; ATRX shRNA; 
Trp53 CRISPR; PDGFRA 
This paper N/A 
Mouse ex vivo NPCs: K27M H3.3-GFP; ATRX shRNA; 
Trp53 CRISPR; PDGFRA 
This paper N/A 
Ex vivo tumor: K27M H3.3-GFP; control shRNA; Trp53 
CRISPR 
This paper N/A 
Ex vivo tumor: K27M H3.3-GFP; ATRX shRNA; Trp53 
CRISPR 
This paper N/A 
 Ex vivo tumor: K27M H3.3-GFP; ATRX shRNA; Trp53 
CRISPR; PDGFRA 
This paper N/A 
Experimental Models: Organisms/Strains 
Mouse: C57BL/6J Jackson Laboratory Stock No: 000664 
Mouse: NOD scid Jackson Laboratory Stock No: 001303 
Oligonucleotides 
H3.3 FW Thermo Fisher 
Scientific   
ATGGCACGTACCA
AGCAAACA 
H3.3-HA REV Thermo Fisher 





ATRX shRNA Thermo Fisher 
Scientific   
TTCATTTACATTCT
CATCCGTG 
Control shRNA Thermo Fisher 
Scientific   
CGGCTGAAACAAG
AGTTGG 
PDGFRA FW Thermo Fisher 
Scientific   
ATGGGGACCTCCC
ACCAG 
PDGFRA REV Thermo Fisher 
Scientific   
CAGGAAGCTGTCC
TCCACCAG 
TdTomato FW Thermo Fisher 
Scientific   
ATGGTGAGCAAGG
GCGAG 
TdTomato REV Thermo Fisher 




PB-CAG-GFP Chen and LoTurco, 
2012 
N/A 
PB-U6-empty Chen and LoTurco, 
2012 
N/A 
CAG-PBase Chen and LoTurco, 
2012 
N/A 
pcDNA5FRT-EF-Pdgfralpha-EGFPN L. Pedersen Addgene Plasmid 
#66787 
pcDNA5FRT-EF-Pdgfralpha-EGFPN D842V L. Pedersen Addgene Plasmid 
#66789 
PB-CAG-H3.3WT-2A-GFP This paper N/A 
PB-CAG-H3.3G34R-2A-GFP This paper N/A 
PB-CAG-H3.3K27M-2A-GFP This paper N/A 
PB-CAG-PDGFRAWT-PQR-TdTomato This paper N/A 
PB-CAG-PDGFRAWT This paper N/A 
PB-CAG- PDGFRAD842V-PQR-TdTomato This paper N/A 
PB-CAG- PDGFRAD842V This paper N/A 
pX330 control guide RNA Zuckermann et al., 
2015 
N/A 
pX330 p53 guide RNA Zuckermann et al., 
2015 
N/A 
PB-U6 control shRNA This paper N/A 
PB-U6 ATRX shRNA This paper N/A 
Software and Algorithms 
Trimmomatic v0.32 Bolger et al., 2014 http://www.usadellab
.org/cms/index.php?
page=trimmomatic 
 STAR v2.3.0e Dobin et al., 2013 https://github.com/al
exdobin/STAR 
featureCounts v1.4.4 Liao et al., 2014 http://bioinf.wehi.edu
.au/featureCounts/ 




FASTQC v0.11.2 N/A http://www.bioinform
atics.babraham.ac.u
k/projects/fastqc/ 
Samtools v0.1.19 Li et al., 2009 https://github.com/sa
mtools/samtools 




UCSC tools  https://genome.ucsc.
edu/util.html 





GenePattern ssGSEAProjection v6 Kuehn et al., 2008 http://software.broadi
nstitute.org/cancer/s
oftware/genepattern 




bwa v0.7.10-r789 Jo and Koh, 2015 http://bio-
bwa.sourceforge.net/ 






Zen microscope software Zeiss N/A 
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Supplemental Text and Figures Click here to download Supplemental Text and Figures
supplementary_material_220917.pdf
Figure S1. Related to Figure 1. H3.3K27M expression is embryonic lethal, while targeted 
expression via the Nes promoter or in postnatal animals fails to induce tumorigenesis. 
(A) Schematic describing strategy for engineering knock-ins of H3.3 mutations. Zinc finger 
nuclease (ZFN1 and ZFN2)-mediated targeting of the endogenous mouse H3f3a locus and 
allelic replacement mediates the exchange of the wild-type exon 2 with an exon 2 harboring 
K27M or G34R mutations, and introduces ZFN1 and ZFN2 G>C binding site mutations to 
prevent re-excision. Bar graph below shows number of FVB/N-C57BL6 hybrid embryos with 
ZFN-mediated double knock-in of K27M reaching the morula/blastocyst stage, compared to 
WT embryos. Genomic DNA from embryos at 2-cell, 4-cell and morula blastocyst stages was 
sequenced for ZFN1 G>C binding site mutations. (B) Schematic describing targeting of mutant 
H3.3HA (G34R or K27M) and luciferase expression downstream of the NPC-specific Nes 
promoter in mice. Detection of luciferase activity and nuclear HA in vivo. Scale bar represents 
100 m. (C) Summary of neonatal injections carried out with different combinations of Sleeping 
Beauty transposable vectors, their respective ratios and DNA concentrations. All experiments 
used SB13/fluc transposase and mice < 48 hours old. EV-HA was used as negative control 
and NRAS-G12V + SV40-LgT were used as positive controls. (D) Demonstration of 
bioluminescence in vivo following injection of luciferase-encoding Sleeping Beauty 
transposable vectors and intraperitoneal luciferin administration. (E) Results of neonatal 
transduction using Sleeping Beauty transposons. NRAS-G12V + SV40-LgT was used as a 
positive control.  
 
  Table S1. Related to Figures 1, 2, 3 and 6. Summary of tumor penetrance at different timepoints and histological features. 
 
 
      Tumor features 





EV control cortex 0 0 0 3       
WT control cortex 0 0 0 4       
G34R control cortex 0 0 0 7       
K27M control cortex 
few Ki67+ cells, 
dispersed 
few Ki67+ cells, 
dispersed 0 3       
WT-P hindbrain 0 0 0 3       
G34R-P hindbrain 0 0 0 2       
K27M-P hindbrain 3 undetermined N/A 3 0 3 0 
K27M-P cortex 2 5 100% 7 7 0 0 
EV-AP cortex 0 0 0 11       
WT-AP cortex 0 0 0 8       
G34R-AP cortex 0 0 0 11       
K27M-AP cortex 11 6 100% 17 6 11 0 
EV-PDGFRA 
control cortex 0 undetermined N/A 4       
EV-APP cortex 1 2 25% 12       
WT-APP cortex 1 0 10% 10       
G34R-APP cortex 0 2 18% 11       
K27M-APP cortex 11 6 100% 17 0 17 6 
EV-APD842V cortex 5 undetermined 100% 5 0 5 5 
WT-APD842V cortex 5 undetermined 100% 5 0 5 5 
G34R-APD842V cortex 5 undetermined 100% 5 0 5 5 
K27M-APD842V cortex 5 undetermined 100% 5 0 5 5 




























































Figure S2. Related to Figure 2. K27M-AP tumor cells migrate ventrally and/or 
contralaterally and reduce ongoing postnatal neurogenesis.  (A) Coronal sections 
demonstrating GFP+ signal in EV-AP, WT-AP and two different biological replicates of K27M-
AP brains 4 months following surgery. Scale bars represent 1.5 mm. (B) Quantification of total 
GFP+ area in EV-AP, WT-AP and K27M-AP coronal sections. Data are represented as mean 
+ SEM. (C) Neuron-to-astrocyte ratio in WT-AP compared to EV-AP. Data are represented as 
mean + SEM. (D) Representative examples of number of subventricular zone (SVZ)-derived 
neurons in the olfactory bulb in EV-AP, WT-AP and K27M-AP. Scale bars represent 50 m. 
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Figure S3. Related to Figure 3. In utero delivery of piggyBac-transposable mutant 
PDGFRAD842V along with knockdown of ATRX and p53 results in aggressive 
tumorigenesis and death by P28-P35, independent of H3.3K27M. (A) Histology of mutant 
PDGFRAD842V-driven GFP+ tumor containing Ki67+ cells. Scale bars represent 1 mm (top) and 
100 µm (bottom). (B) Mutant PDGFRAD842V-driven tumors display both Olig2+ and GFAP+ 
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Figure S4. Related to Figure 4. Targeted drug screen of K27M tumor cells using a small 
molecule library of 430 kinase inhibitors. (A) Viability change and standard deviations are 
shown for Vacquinol-1 responses in K27M-AP and Akti-1/2 responses in K27M-APP. 
Vacquinol-1 and Akti-1/2 wells are highlighted in green and with the letters “V” and “A”, 
respectively. “P” and “N” indicate positive and negative controls, respectively. (B) Distribution 
of raw (left panel) and normalized values (right panel) for all plates. The graphs show the 
median and variant distribution of signals in each plate. Each box displays the distribution of 
values based on minimum (low outlier), first quartile (low margin of box), median (line in the 
middle of the box), third quartile (top margin of box), and maximum (high outlier) of 
raw/normalized measured signals. (C) Distribution of controls in each plate. The left plot 
presents the signal from positive and negative controls at each plate and also the extension 
between positive contol (Celexocib indicated by red dots) and negative control (DMSO 
indicated by blue dots). The right plot shows the high Z‘-factor (0.73) value, with another 
overview on positive and negative controls, obtained from kernel density estimates. 
 
AB
Figure S5. Related to Figure 5. Homogeneity of the mutational landscape of 10 spatial 
biopsies of a K27M-AP tumor. (A) Clonality analysis of spatial biopsies of a K27M-AP tumor 
reveals 6 distinct clusters of SNVs. The set of SNVs used here are good-quality, non-
synonymous SNVs that occur in gene exons. Each line corresponds to the cellular prevalence 
(y-axis) of each SNV cluster (identified by color) across the 10 spatial biopsies (x-axis). The 
error bars for each point indicate the standard deviation of the cellular prevalence of the 
constituent SNVs of each cluster in each biopsy. Inset shows GFP+ regions in the K27M-AP 
tumor used in this analysis. The regions shown within dashed lines were dissected for exome 
analysis. Scale bars represent 1.5 mm. (B) Comparisons of variant allele frequencies (VAF) 
of the constituent SNVs of the clusters determined in (A) between pairs of biopsies. Each point 
corresponds to an individual SNV, colored by the cluster to which it belongs, with its (x, y) 
coordinates representing its VAF in pairs of biopsies. Maximum concordance of VAFs appears 
as a y = x line through the origin (shown here between the same biopsies). Error bars indicate 









































Figure S6. Related to Figure 6. PDGFRAWT overexpression increases the migration 
capacity of K27M-APP tumor cells and promotes a glial morphology or fate in the 
olfactory bulb. (A) Coronal sections demonstrating GFP+ signal in EV-APP, WT-APP and 
two different biological replicates of K27M-APP brains at 4 months following surgery. Scale 
bar represent 1.5 mm. (B) Quantification of total GFP+ area in EV-APP, WT-APP and K27M-
APP coronal sections. One WT-APP low-penetrance tumor is marked “T”. Data are 
represented as mean + SEM. (C) Representative examples of number and morphology of 
subventricular zone (SVZ)-derived cells in the olfactory bulb in EV-APP, WT-APP and K27M-












































































































































































































Figure S7. Related to Figure 7. H3.3K27M-dependent transformation induces 
transcriptomic changes that are recapitulated in human tumors. (A) Principal component 
analysis (PCA) visualization of the murine samples based on transcriptome-wide expression 
level data. Black: EV ctl and EV PDGFRA. Blue: WT-AP. Orange: preneoplastic K27M cells 
(K27M). Red: K27M tumors (K27M-T). (B) Expression levels of Pdgfra across the cohort of 
RNA-Seq samples. RPKM values are reported here. (C) t-Embedded Neighbor Embedding (t-
SNE) visualization of human samples based on the expression of the 870 most variant genes 
across human samples, illustrating the inferior separation of H3.3WT and H3.3K27M pHGG 
samples when human orthologs of the murine K27M-T signature (Figure 7A) are not used. 
Black: normal brain (NB). Grey: H3.3WT pHGG. Red: H3.3K27M pHGG. 10,000 iterations were 
performed on the PCA space (first 50 PCs) with perplexity=2, theta=0. Segregation of the 
three groups is specific to the K27M-T signature, and not obtained when using most variant 
genes (Figure 7B). (D-E) An analogous analysis of Figure 7C (D) and Figure S7C (E) using 
PCA visualization reveals the superior separation of H3.3WT and H3.3K27M pHGG samples 
through use of the human orthologs of the K27M-T signature. Black: normal brain (NB). Grey: 
H3.3WT pHGG. Red: H3.3K27M pHGG. (F) Genes specifically related to chromatin, homeobox, 
Wnt and DNA binding in the murine K27M-T signature are recapitulated in human H3.3K27M 
pHGG (i.e. human tumors carrying H3.3K27M mutations, Trp53 loss-of-function mutations and 
moderate-to-high levels of Pdgfra). Reported here are the respective single-sample Gene Set 
Enrichment Analysis (ssGSEA) scores of each signature in human samples. Signature 
subsets were extracted from the murine K27M-AP complete signature using functional 
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Figure S8. Related to Figure 8.  K27M-induced alteration of genome-wide H3K27me3 
deposition is captured by the mouse model. (A) Complete heatmap illustrating H3K27me3 
levels at transcription start sites (TSSs) of all murine genes. H3K27me3 levels in regions of 
10Kb surrounding TSSs (in rows) were normalized locally on a per-sample basis (in columns; 
from left-to-right: EV-ctl, EV-PDGFRA, K27M-AP T, K27M-APP T) and genes were 
subsequently clustered by k-means into k=12 clusters based on average perigenic H3K27me3 
levels in each sample. Clusters M1-M4 consist of genes strongly regulated by H3K27me3; 
cluster M5 represents genes consistently depleted in the mark; and clusters M6 and upper M7 
represent losses in H3K27me3 boundaries. The remaining clusters M8-M12 exhibit differing 
degrees of intra-cluster uniformity of H3K27me3 deposition and less consistently distinctive 
losses of the H3K27me3 along gene bodies. H3.3 WT: EV-ctl, EV-PDGFRA. K27M: K27M-AP 
T /K27M-APP T. (B) The distribution of changes in expression levels of deregulated genes in 
each of the clusters reveals a clear trend toward upregulation across most clusters (M1-M5, 
M8-M9, M12). Only significant gene expression changes are reported, in the form of log2 fold-
change in K27M-T relative to baseline controls. (C) Pairwise similarity matrix between murine 
(rows) and human (columns; Figure 8C) gene clusters. Similarity was measured as the 
proportion of mouse genes with human orthologs present in each human cluster. While 
clusters M1-M5 exhibit more distinctive differences between H3.3WT (EV-ctl and EV-PDGFRA) 
and H3.3K27M (K27M-AP T, K27M-APP T) samples, clusters M6-M12 display variable degrees 
of recapitulation with human gene clusters. (D) De novo deposition of the H3K27me3 mark at 
the loci of Hlx, Igf2bp3, and Socs2 in H3.3K27M-tumors in spite of a global reduction in 
H3K27me3 levels. PDGFRA-independent increase in H3K27me3 levels that is specific to 
locus of Hlx but not to neighboring regions (see to the right). Increase in H3K27me3 levels in 
the promoter region of Igf2bp3 in K27M-P T and K27M-AP T. Increase in H3K27me3 levels 
unique to K27M-AP T from the region upstream of Socs2 followed by a loss of the mark when 
compared to controls (EV/WT-AP). 
 
